• Study on Reducing Chronic Migraine Days with CGRP Antibodies and Botulinum Toxin A in Adults Aged 18-70

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Norway

  • Study of Relacorilant, Nab-Paclitaxel, and Bevacizumab for Patients with Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Germany Italy Poland Spain

  • Study on the Safety and Effects of ORX750 for Patients with Narcolepsy and Idiopathic Hypersomnia

    Recruiting

    2 1
    Investigated Drugs:
    France Italy Spain

  • Study on Faster Weaning from Ventilators in Critically Ill Patients Using Levosimendan and a Drug Combination

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands

  • Study on Epcoritamab for Patients with Relapsed or Refractory Large B Cell Lymphoma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    Spain

  • Study of Tezepelumab Compared to Placebo in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia Denmark Germany Italy Poland Slovakia +1

  • Study on ITI-1284 for Treating Psychosis in Alzheimer’s Patients

    Recruiting

    2 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria Croatia Czechia Italy Poland Romania +2

  • Study of ENTR-601-45 Safety and Effectiveness in Patients with Duchenne Muscular Dystrophy Who Can Skip Exon 45

    Recruiting

    2 1 1
    Investigated Drugs:
    Belgium France Ireland Italy The Netherlands Poland +1

  • Study on IPN10200 for Treating Cervical Dystonia in Adults

    Recruiting

    2 1
    Investigated Drugs:
    Czechia France Germany Italy Poland Spain

  • Study on Atorvastatin to Prevent Atherosclerosis Progression in Patients Undergoing Immune Checkpoint Inhibitor Therapy

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands

powered by